MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)

Acute myeloid leukemia (AML) is a clonal heterogenous malignancy of the myeloid cells with a poor prognosis lending itself to novel treatment strategies. TP53 is a critical tumor suppressor and plays an essential role in leukemogenesis. Although TP53 is relatively unusual in de novo AML, inactivatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Khurana, Arushi, Shafer, Danielle A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563714/
https://www.ncbi.nlm.nih.gov/pubmed/31289443
http://dx.doi.org/10.2147/OTT.S172315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563714/
https://www.ncbi.nlm.nih.gov/pubmed/31289443
http://dx.doi.org/10.2147/OTT.S172315

Ejemplares similares